Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PHAR253 > COPD > Flashcards

COPD Flashcards

1
Q

What is COPD?

A

respiratory disorder largely caused by smoking that is characterized by:
-progressive, partially reversible airway obstruction
-lung hyperinflation
-systemic manifestations
-increasing frequency and severity of exacerbations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is emphysema?

A

abnormal enlargement of the airspace distal to the terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is chronic bronchitis?

A

chronic cough for at least 3 months x 2 consecutive years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Provide a brief overview of the epidemiology of COPD.

A

772,200 (4%) Canadians >35yrs with COPD
cigaretter smoking is the principle underlying cause of COPD
-responsible for 80% of deaths
3rd leading cause of death worldwide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the non-host risk factors for COPD?

A

exposure to particles
-cigarette smoking/exposure to 2nd hand smoke
-occupational dusts, organic and inorganic
-outdoor air pollution
-indoor air pollution
infections
-frequent childhood respiratory problems/prior TB or HIV
socio-economic factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the most significant risk factor for COPD

A

cigarette smoking/exposure to 2nd hand smoke

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the host risk factors for COPD?

A

genetics: 1-antitrypsin deficiency
age (because of particle exposure?)
lung growth and development
airway hyper-responsiveness
-asthma=increased risk?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is 1-antitrypsin?

A

serum protein produced by the liver and normally found in lungs
prevents neutrophil elastase from destroying lung tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the pathophysiology of COPD?

A

stimulus (smoking)–>inflammatory process–>narrowing of peripheral airways–> reduced FEV1
-oxidative stress may play an important role in amplifying the inflammatory process
-a protease-antiprotease imbalance is noted in the lungs of COPD patients (protease mediated destruction of elastin)
-increased CD8 and other inflammatory mediators induce structural changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe expiratory flow limitation as part of the pathophysiology of COPD.

A

hallmark of COPD
due to increased resistance from mucosal inflammation, airway remodeling, fibrosis & secretions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe lung hyperinflation as part of the pathophysiology of COPD.

A

obstruction of the small airways results in air-trapping which causes lung hyperinflation
develops early in disease and causes exertional dyspnea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe gas exchange abnormalities as part of the pathophysiology of COPD.

A

results in hypoxemia & hypercapnia
gas transfer for O2 & CO2 worsens as disease progresses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe mucous hypersecretion as part of the pathophysiology of COPD.

A

results in chronic productive cough
not necessarily associated with airflow limitation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe exacerbations as part of the pathophysiology of COPD.

A

triggered by infection, environmental pollutants or unknown
during exacerbations there is increased hyperinflation and gas trapping with decreased expiratory flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe significant comorbid illness as part of the pathophysiology of COPD.

A

pulmonary HTN may develop late in course of COPD due to hypoxic vasoconstriction of small pulmonary arteries
muscle wasting and cachexia, skeletal muscle dysfunction
osteoporosis, depression, anemia, metabolic syndrome, CV, lung disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the three cardinal symptoms of COPD?

A

phlegm
chronic cough
shortness of breath

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Aside from the cardinal symptoms, what are some other symptoms of COPD?

A

barrel-shaped chest
fatigue
frequent lung infections
unexplained weight loss
reduced ability for daily activities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the end-stage symptoms of COPD?

A

adopt positions that relieve dyspnea
use of accessory respiratory muscles
expiration through pursed lips
cyanosis
enlarged liver from right heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How do patients initially present with COPD?

A

sedentary lifestyle and general fatigue
-avoiding exertional dyspnea
-shifted expectations and limited their activities
complains of dyspnea and chronic cough
-initially noted on exertion only
-progressively triggered by less exertion
-morning sputum production
episodes of cough, sputum, wheezing, fatigue, and dyspnea
-intervals between episodes shortens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Differentiate asthma and COPD using the following parameters:
-age on onset
-smoking history
-sputum production
-allergies
-clinical symptoms
-disease course
-importance of co-morbid illness
-spirometry
-airway inflammation
-response to ICS
-role of bronchodilators
-role of exercise training
-end of life discussions

A

age on onset
-COPD: usually >40 yrs
-asthma: usually <40 yrs
smoking history
-COPD: usually >10 pack-years
-asthma: not causal, but worsens control
sputum production
-COPD: often
-asthma: infrequent
allergies:
-COPD: infrequent
-asthma: often
clinical symptoms
-COPD: persistent and progressive
-asthma: intermittent and variable
disease course
-COPD: progressive worsening
-asthma: stable
importance of co-morbid illness
-COPD: often important
-asthma: often important
spirometry
-COPD: may improve but never normalizes
-asthma: often normalizes
airway inflammation
-COPD: neutrophilic
-asthma: eosinophilic
response to ICS
-COPD: helpful in mod-severe dx and freq AECOPD
-asthma: essential for optimal control
role of bronchodilators
-COPD: regular therapy usually necessary
-asthma: prn only
role of exercise training
-COPD: essential therapy
-asthma: rarely formally used
end of life discussions
-COPD: often essential
-asthma: rarely necessary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

When should we consider a clinical diagnosis for a patient?

A

any patient who has:
-dyspnea
-chronic cough
-sputum production
-history of exposure to risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is required to make a diagnosis of COPD?

A

spirometry
spirometry post-bronchodilator FEV1/FVC ratio <0.7 confirms diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

True or false: evidence supports population screening with spirometry for COPD

A

false

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Which patients should be screened for COPD?

A

smokers/ex-smokers >40yrs who have:
-persistent cough or sputum production
-frequent respiratory tract infections
-progressive activity-related SOB
-evening wheeze

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What are some good questions to ask when screening someone for COPD?
do you cough regularly do you cough up phlegm regularly? do even simple chores make you short of breath? do you wheeze when you exert yourself or at night? do you get frequent colds that persist longer than those of other people? *IF YES-->SPIROMETRY*
26
What are the steps in the clinical evaluation of COPD?
1. pulmonary function testing -must determine degree of reversibility -FEV1 <80% and FEV1/FVC ratio <0.7 2. assessment of risk factors -quantification of tobacco consumption -record environmental exposures 3. assessment of severity of breathlessness using the MRC dyspnea scale or CAT test 4. assessment of frequency and severity of exacerbations 5. assessment of symptoms that could point to complications 6. assessment of the symptoms that suggest comorbidities 7. assessment of medications
27
Describe the mMRC dyspnea scale.
grade 0: -breathless with strenuous exercise grade 1: mild -SOB when hurrying on level or walking uphill stage 2: moderate -walks slower than people of same age on level or stops for breath while walking at own pace on same level stage 3: moderate -stops for breath after walking 100m or after few mins on same level stage 4: severe -too breathless to leave house, or dressing
28
What is the CAT test?
validated, short and simple patient completed questionnaire reliable measure of the impact of COPD on a patients health status score ranging from 0-40: -0-10=low impact -10-20=medium impact -21-30=high impact ->30=very high impact
29
What is the spirometry that can diagnose someone with COPD?
post bronchodilator FEV1 <80% predicted FEV1/FVC ratio < 70%
30
What are the corresponding spirometry values for the stages of COPD?
mild: -FEV1 >80% predicted -FEV1/FVC ratio <0.7 moderate: -FEV1 50-79% predicted -FEV1/FVC ratio <0.7 severe: -FEV1 30-49% predicted -FEV1/FVC ratio <0.7 very severe: -FEV1 <30% predicted -FEV1/FVC <0.7
31
How is FEV1 used in assessing COPD?
used to stage/assess severity
32
What are the goals of treatment for COPD?
prevent disease progression prevent and treat exacerbations alleviate breathlessness and other respiratory symptoms improve exercise tolerance and daily activity prevent and treat complications of the disease improve health status reduce mortality
33
What are the 8 possible treatments of COPD?
smoking cessation eliminate occupation/environmental exposures comprehensive patient/family education avoid sedatives/narcotics in severe disease rehabilitation programs vaccines long-term oxygen therapy pharmacologic therapy
34
What is the single most effective intervention to reduce the risk of COPD and the only intervention that has been shown to slow its progression?
smoking cessation
35
What are the five A's of smoking cessation?
ask advise assess assist arrange
36
What are the important aspects of comprehensive patient/family education for COPD?
expectations of therapy must be discussed self management plans -Rxs for oral steroids and antibiotics to fill prn -advanced care directives inhaler technique -select best device for each patient
37
Why should sedatives/narcotics be avoided in severe disease?
increased sensitivity to respiratory depression especially when sleeping
38
What are some examples of pulmonary rehabilitation programs?
respiratory, physical and occupational therapy exercise conditioning nutritional counseling psychosocial support vocational rehabilitation
39
True or false: COPD patients should not carry out an active lifestyle
false all COPD patients should be encouraged to maintain an active lifestyle
40
What are the benefits of pulmonary rehabilitation?
reduced dyspnea increased exercise endurance improved quality of life reduced leg discomfort decreased fatigue reduced resource utilization related to AECOPD trend toward reduced mortality
41
Which vaccinations are recommended for COPD patients?
influenza pneumococcal COVID
42
Describe oxygen therapy for COPD.
does not change pulmonary function cornerstone of therapy -improves quality/duration of life in selected patients assess patient when stable goal PaO2 > 60mmHg
43
What is the mainstay of treatment for COPD?
bronchodilators -larger doses may be used compared to treatment in asthma
44
What is the role of muscarinic antagonists and ICS for COPD compared to asthma?
muscarinic antagonists have larger role ICS have less of a role
45
What should you investigate if a bronchodilator has failed for a COPD patient?
technique and compliance
46
What is an example of a SAMA? What is its dosing frequency?
ipratropium -QID prn
47
What is the use of short acting bronchodilators in all stages of COPD treatment?
prn use -higher doses=more bronchodilation -may increase beyond recommended dose in severe disease
48
What is the MOA of SAMAs and LAMAs?
competitively inhibit cholinergic receptors in bronchial smooth muscle -blocks ACh which reduces cGMP -airway muscle tone is partially controlled by cholinergic innervation
49
Compare SAMAs to SABAs in terms of efficacy and onset.
SAMAs are less effective than B2 agonists in asthma slower onset of action than SABA
50
What are the adverse effects of SAMAs and LAMAs?
dry mouth (rinse mouth after) cough constipation urinary retention headache avoid eye contact (can precipitate glaucoma)
51
What are examples of LAMAs?
tiotropium glycopyrronium aclidinium umeclidinium
52
Compare LABAs and LAMAs.
both improve symptoms LAMA may be superior in decreasing exacerbations LAMA may be better tolerated side effects profile vary: -LAMA: dry mouth, constipation -LABA: headache, dose dependent CV effects cost is similar
53
True or false: just like asthma, ICS are used 1st line in COPD
false
54
Why are ICS not used first line in COPD?
evidence for reducing exacerbations but inconsistent evidence for symptom improvement consider ICS AEs (increased risk of pneumonia)
55
Which COPD patients might respond better to ICS?
those with higher eosinophil count
56
What is the dosage regimen of prophylactic azithromycin in COPD?
250mg OD x 1yr -lower exacerbation rates and improved QOL -higher rate of macrolide-resistant bacteria and hearing deficits -may also see dosed 3x weekly
57
Which patients would be eligible for prophylactic azithromycin?
normal QT interval no significant DIs no evidence of indolent or active infection with atypical mycobacteria
58
What is the role of N-acetylcysteine in COPD?
600mg po BID may be of benefit in reducing acute exacerbations in those who had 2 or more exacerbations in the previous 2 yrs -optimal dose has not been determined -mucolytic agent with antioxidant properties
59
Which phenotype of COPD is at higher risk of exacerbations from NAC?
chronic bronchitis
60
What is the MOA of roflumilast?
phosphodiesterase inhibitor
61
What is the role of roflumilast in COPD? What is its dose?
add-on to bronchodilator treatment could be considered for addition to existing triple therapy (LAMA/LABA/ICS) for ppl with COPD who have had at least 1 exacerbation in the past year not to be used as rescue medication dose: 500mcg po OD
62
What are the side effects of roflumilast?
diarrhea, weight loss, nausea, headache, sleep disturbances neuropsych effects (avoid in hx of depression with suicidal ideation) *less tolerated than inhaled meds*
63
True or false: theophylline is still in the COPD guidelines
false
64
Differentiate between the different severities of AECOPD.
mild exacerbation: -worsening or new respiratory symptoms without a change in medications moderate exacerbation: -prescribed antibiotic and/or po corticosteroid severe exacerbation: -requiring a hospital admission or ED visit
65
Differentiate between low-risk of exacerbation and high-risk of exacerbation.
low-risk: -1 or less moderate exacerbations in the last year and did not require ED or hospital high-risk: -at least 2 moderate or 1 severe exacerbation in last yea requiring ED or hospital
66
What is the treatment algorithm for COPD?
mild: CAT <10, mMRC 1, FEV1>80% -LAMA or LABA moderate and severe: CAT >10, mMRC >2, FEV1<80 -low AECOPD risk: LAMA/LABA*, LAMA/LABA/ICS -high AECOPD risk: LAMA/LABA/ICS**, LAMA/LABA/ICS +prophylactic macrolide/PDE4i/mucolytic agents *all have short-acting bronchodilator prn*
67
What are two possible surgeries that can be considered for a COPD patient?
lung volume reduction surgery lung transplantation -5 year survival rate is ~60%
68
Describe stepping up treatment of COPD.
*usually treatment is progressive and additive* no absolute interval at which evaluation should be performed after initiating change in therapy, consider 6months after initialing long acting bronchodilator and 12 months after initiating ICS
69
Describe stepping down treatment in COPD.
questionnable...may be considered -if benefits not realized or AE>benefits -patients on ICS at low risk of morbidity/mortality and long period of stability close supervision and monitoring necessary
70
What is the definition of an acute COPD exacerbation?
sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medications and/or supplementation medications
71
What is the most frequent cause of medical visits, hospitalizations and death among COPD patients?
acute exacerbations
72
What are the consequences of AECOPD?
reduced health-related quality of life increased mortality increased health resource utilization and costs accelerated decline in lung function
73
What is the treatment of AECOPD?
bronchodilators (salbutamol+/-ipratropium) -SAMA and SABA become scheduled -increase dose and frequency -long acting inhalers can be continued but should not replace short acting dilators systemic steroids -improve spirometry; decrease relapse rate -restore lung function quicker consider antibiotics -should be given to patients requiring mechanical ventilation -patients with at least 2/3 cardinal symptoms
74
What is the typical dose of systemic steroids for AECOPD?
30-50mg daily prednisone (or equiv) x 5-14d
75
What percentage of AECOPD are thought to be infectious in nature?
50% -many are viral and remainder are due to bacterial infection
76
What is the antibiotic choice for AECOPD for patients without risk factors?
amoxicillin doxycycline cotrimoxazole *5-7 days*
77
What is the antibiotic choice for AECOPD for patients with risk factors?
amoxiclav (5-10d) cefuroxime (5-10d) levofloxacin (3-5d)
78
Who should be hospitalized for AECOPD?
severe symptoms acute respiratory failure physical symptoms (cyanosis, edema) failure to respond to initial management presence of serious comorbidities insufficient home support
79
What is the discharge criteria following AECOPD?
B2 agonist required no more than q4h patient able to walk across room patient able to eat and sleep without dyspnea clinically stable for 12-24h arterial blood gases stable for 12-24h patient understands correct use of meds follow-up and home care arrangements complete health care team is confident
80
Which LAMA is dosed BID?
aclidinium *the other three are dosed OD*
81
Which LAMAs accumulate in renal impairment?
tiotropium glycopyrronium
82
What is the onset of LAMAs?
within minutes *LABAs also work within minutes*
83
What are the factors that should have us suspect COPD in a patient?
age > 40 smoker or ex smoker progressive dyspnea, worse with exercise
84
Can there be overlap between asthma and COPD?
growing recognition that patients may have concurrent symptoms no consensus on definition

PHAR253 (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions